KPTI Logo

Karyopharm Therapeutics Inc. (KPTI) 

NASDAQ
Market Cap
$109.77M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
597 of 776
Rank in Industry
321 of 433

Largest Insider Buys in Sector

KPTI Stock Price History Chart

KPTI Stock Performance

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with …

Insider Activity of Karyopharm Therapeutics Inc.

Over the last 12 months, insiders at Karyopharm Therapeutics Inc. have bought $0 and sold $1.8M worth of Karyopharm Therapeutics Inc. stock.

On average, over the past 5 years, insiders at Karyopharm Therapeutics Inc. have bought $130,090 and sold $4M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 41,140 shares for transaction amount of $49,985 was made by BOHLIN GAREN G (director) on 2023‑09‑12.

List of Insider Buy and Sell Transactions, Karyopharm Therapeutics Inc.

2024-11-05SalePresident and CEO
3,675
0.0029%
$0.91$3,346-3.32%
2024-10-04SalePresident and CEO
3,607
0.0036%
$0.88$3,172-3.74%
2024-09-04SalePresident and CEO
3,667
0.003%
$0.72$2,647+18.09%
2024-09-04SaleEVP & Chief Commercial Officer
5,356
0.0044%
$0.72$3,866+18.09%
2024-09-04SaleEVP, CFO & Treasurer
7,050
0.0057%
$0.72$5,089+18.09%
2024-09-04SaleSVP, General Counsel&Secretary
3,971
0.0032%
$0.72$2,866+18.09%
2024-08-06SalePresident and CEO
3,608
0.0032%
$0.93$3,355-3.25%
2024-07-30SaleEVP, Chief Development Officer
2,883
0.0023%
$1.06$3,056-12.86%
2024-07-05SalePresident and CEO
3,616
0.0025%
$0.85$3,0770.00%
2024-06-07Saledirector
2,240
0.0018%
$0.95$2,130-11.71%
2024-06-06Saledirector
118,452
0.096%
$0.98$116,415-12.84%
2024-06-05Saledirector
468,044
0.3619%
$0.96$448,480-14.62%
2024-06-04SalePresident and CEO
3,592
0.0033%
$0.99$3,556-8.38%
2024-06-04SaleEVP, CFO & Treasurer
652
0.0006%
$0.99$645-8.38%
2024-06-04Saledirector
341,040
0.2976%
$0.95$324,704-8.38%
2024-06-03Saledirector
360,744
0.3105%
$1.00$360,997-12.96%
2024-05-31Saledirector
204,394
0.1709%
$0.95$194,992-11.09%
2024-05-06SalePresident and CEO
3,576
0.003%
$1.13$4,041-22.83%
2024-04-22SaleEVP & Chief Medical Officer
6,789
0.006%
$1.17$7,943-18.81%
2024-04-04SalePresident and CEO
3,563
0.003%
$1.29$4,596-28.71%

Insider Historical Profitability

3.75%
PAKIANATHAN DEEPIKAdirector
0
0%
$0.8857+36.66%
Frenkel RanEVP, Chief Dev. Officer
168290
0.135%
$0.8829<0.0001%
Shah JatinEVP, Chief Medical Officer
129450
0.1038%
$0.8816<0.0001%
Brannelly PaulSVP, FINANCE & ADMIN, TREAS
66136
0.053%
$0.8830+28.23%
BOHLIN GAREN Gdirector
45140
0.0362%
$0.8820<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$14.27M8.039.45M-6.2%-$942,238.50<0.0001
The Vanguard Group$12.59M7.088.34M-4.27%-$561,353.09<0.0001
Avidity Partners Management Lp$12.53M7.058.3M0%+$00.48
Palo Alto Investors Lp$7.7M4.345.1M0%+$00.87
Eversept Partners LP$7.57M4.265.02MNew+$7.57M0.58
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.